tags. Meta description 150-160 chars. Keywords: Eli Lilly, Mounjaro, Zepbound, GLP-1, obesity drug market. Focus keyword: Eli Lilly Q2 earnings. Let's write. Title: "Eli Lilly Q2 Revenue Jumps 48% to $23B on Mounjaro, Zepbound Sales" Slug: "eli-lilly-q2-revenue-jumps-48-percent" Content: Lead: Eli Lilly's second-quarter revenue hit $23 billion, a 48% jump from a year ago, as sales of its GLP-1 drugs Mounjaro and Zepbound kept climbing. The company also raised its full-year revenue guidance to $85-87 billion. Then sections. I'll write the article text, then wrap in HTML. Make sure no invented quotes. We have Jim Cramer and Jeff Marks as named, but we only have their statements as facts: "Jim Cramer and CNBC analyst Jeff Marks called Eli Lilly and Nvidia top momentum stocks." and "Jeff Marks said Eli Lilly's GLP-1 sales are more towards the end of the decade, requiring a longer time horizon." So we can paraphrase those, but not quote them directly unless we have exact words. We can say "Jeff Marks, a CNBC analyst, said..." but we don't have exact quote, so we paraphrase: "Jeff Marks said Eli Lilly's GLP-1 sales are more towards the end of the decade, requiring a longer time horizon." That's a paraphrase of his statement. We can attribute that to him. But we must not invent quotes. So we can write: "Jeff Marks, a CNBC analyst, said Eli Lilly's GLP-1 sales are more towards the end of the decade, requiring a longer time horizon." That's fine. Also Jim Cramer and Jeff Marks called them top momentum stocks - we can say that. Now write. Word count target 500-800. Let's aim ~650. I'll write the article. Lead: Eli Lilly's second-quarter revenue hit $23 billion, up 48% from a year earlier, as sales of its weight-loss and diabetes drugs Mounjaro and Zepbound continued to surge. Management raised its full-year revenue forecast to $85-87 billion, betting the momentum holds. Section 1: "Mounjaro and Zepbound carry the quarter" - Mounjaro sales rose 91% to $9.9 billion worldwide. Zepbound's U.S. revenue grew 44% to $4.9 billion. Sales volume jumped 60%, offsetting a 13% drop in realized prices. Section 2: "International growth and the China price cut" - International revenue jumped 80% to $8.6 billion, with volume up 113%. But prices outside the U.S. fell 36% after Mounjaro was added to China's National Reimbursement Drug List. That's a trade-off. Section 3: "A bigger market, and a longer wait" - Morgan Stanley projects the global obesity and diabetes drug market to reach $190 billion by 2035, up from $79 billion in 2025. Oral GLP-1 pills and expanding insurance coverage are the main drivers. Jim Cramer and CNBC analyst Jeff Marks called Eli Lilly and Nvidia top momentum stocks. Jeff Marks said Eli Lilly's GLP-1 sales are more towards the end of the decade, requiring a longer time horizon. End: That longer time horizon is worth keeping in mind. The stock is up 88% in the last 12 months, and the company is betting on a market that's still taking shape. But we need a concrete next step. Maybe: The company's next earnings report will show whether the raised guidance holds up. Or something like that. But we don't have a specific date. We can say: "Investors will be watching whether the China price cut continues to weigh on international revenue in the coming quarters." That's a concrete unresolved question. Let me write the full content. I'll write in HTML. Also ensure no clichés, no "it remains to be seen", etc. Let me draft. Title: "Eli Lilly Q2 Revenue Jumps 48% to $23B on Mounjaro, Zepbound Sales" Slug: "eli-lilly-q2-revenue-jumps-48-percent" Content: Eli Lilly's second-quarter revenue hit $23 billion, up 48% from a year earlier, as sales of its GLP-1 drugs Mounjaro and Zepbound kept climbing. Management raised its full-year revenue guidance to $85-87 billion, a sign the company expects the momentum to hold.
Mounjaro and Zepbound carry the quarter
Mounjaro, the diabetes drug that's also used for weight loss, brought in $9.9 billion worldwide, a 91% jump. Zepbound, the obesity-specific treatment, saw U.S. revenue grow 44% to $4.9 billion. Overall sales volume rose 60%, which more than offset a 13% drop in realized prices.
International growth and the China price cut
International revenue surged 80% to $8.6 billion, with volume up 113%. But that growth came with a cost. Prices outside the U.S. fell 36% after Mounjaro was added to China's National Reimbursement Drug List. The move opened a huge market but squeezed per-unit revenue.
A bigger market, and a longer wait
Morgan Stanley projects the global obesity and diabetes drug market will reach $190 billion by 2035, up from $79 billion in 2025. Oral GLP-1 pills and expanding insurance coverage are expected to drive that growth. Jim Cramer and CNBC analyst Jeff Marks called Eli Lilly and Nvidia top momentum stocks. Jeff Marks said Eli Lilly's GLP-1 sales are more towards the end of the decade, requiring a longer time horizon.
That longer time horizon is worth keeping in mind. The stock is up 88% in the last 12 months, and the company is betting on a market that's still taking shape. Investors will be watching whether the China price cut continues to weigh on international revenue in the coming quarters.
Eli Lilly's second-quarter revenue hit $23 billion, up 48% from a year earlier, as sales of its GLP-1 drugs Mounjaro and Zepbound kept climbing. Management raised its full-year revenue guidance to $85-87 billion, a sign the company expects the momentum to hold.
Mounjaro and Zepbound carry the quarter
Mounjaro, the diabetes drug that's also used for weight loss, brought in $9.9 billion worldwide, a 91% jump. Zepbound, the obesity-specific treatment, saw U.S. revenue grow 44% to $4.9 billion. Overall sales volume rose 60%, which more than offset a 13% drop in realized prices.
International growth and the China price cut
International revenue surged 80% to $8.6 billion, with volume up 113%. But that growth came with a cost. Prices outside the U.S. fell 36% after Mounjaro was added to China's National Reimbursement Drug List. The move opened a huge market but squeezed per-unit revenue.
A bigger market, and a longer wait
Morgan Stanley projects the global obesity and diabetes drug market will reach $190 billion by 2035, up from $79 billion in 2025. Oral GLP-1 pills and expanding insurance coverage are expected to drive that growth. Jim Cramer and CNBC analyst Jeff Marks called Eli Lilly and Nvidia top momentum stocks. Jeff Marks said Eli Lilly's GLP-1 sales are more towards the end of the decade, requiring a longer time horizon.
That longer time horizon is worth keeping in mind. The stock is up 88% in the last 12 months, and the company is betting on a market that's still taking shape. Investors will be watching whether the China price cut continues to weigh on international revenue in the coming quarters.
